The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.

A composition is described comprising at least one folate which is useful in the treatment of ocular diseases linked to elevated retinal venous pressure.

A composition is described comprising at least one folate which is useful in the treatment of ocular diseases linked to elevated retinal venous pressure.

The use of a composition as antiviral and/or antimicrobial agent, wherein the composition includes at least a positively charged natural or unnatural amino acid, an organic acid, a cationic polymer and a zwitterionic surfactant.

The use of a composition as antiviral and/or antimicrobial agent, wherein the composition includes at least a positively charged natural or unnatural amino acid, an organic acid, a cationic polymer and a zwitterionic surfactant.

Provided is a new means for administering a valuable substance having a fat dissolving action. A microneedle preparation including at least one of a lipolytic agent, a fat dissolving agent, or a fat metabolism promoting agent, the microneedle preparation being intended for fat reduction and/or partial slenderizing and/or skin tightening, and a microneedle preparation including a microneedle array containing a water-soluble polymer as a base and one or more selected from the group consisting of a lipase, a phosphatidylcholine, and deoxycholic acid.

The present invention relates to an alcoholic beverage and a non-alcoholic beverage composition intended for individuals on a Keto diet comprising about 10-25 grams of fat, about 3 grams or less of carbohydrates, about 5 grams or less of protein, 1-2 ounces of a high fat dairy cream, 5-11 ounces of carbonated water, 5 grams or less of medium-chain triglycerides (MCT), about 250 milligrams or less of a carnitine, and wherein the composition is per 12 ounce serving.

The present invention further relates to methods for producing a Keto beverage composition comprising the steps of mixing the beverage formulation ingredients, carbonating the beverage formulation ingredients, and homogenizing and/or pasteurizing the beverage formulation ingredients, wherein said beverage formulation ingredients comprise about 3 grams or less of carbohydrates, about 10-25 grams of fat, about 5 grams or less of protein, about 5 grams or less of medium-chain triglycerides (MCT), about 250 milligrams or less of a carnitine, and about 5 grams or less of a creatine, and wherein the composition is per 12 ounce serving.

The present invention relates to an alcoholic beverage and a non-alcoholic beverage composition intended for individuals on a Keto diet comprising about 10-25 grams of fat, about 3 grams or less of carbohydrates, about 5 grams or less of protein, 1-2 ounces of a high fat dairy cream, 5-11 ounces of carbonated water, 5 grams or less of medium-chain triglycerides (MCT), about 250 milligrams or less of a carnitine, and wherein the composition is per 12 ounce serving.

The present invention further relates to methods for producing a Keto beverage composition comprising the steps of mixing the beverage formulation ingredients, carbonating the beverage formulation ingredients, and homogenizing and/or pasteurizing the beverage formulation ingredients, wherein said beverage formulation ingredients comprise about 3 grams or less of carbohydrates, about 10-25 grams of fat, about 5 grams or less of protein, about 5 grams or less of medium-chain triglycerides (MCT), about 250 milligrams or less of a carnitine, and about 5 grams or less of a creatine, and wherein the composition is per 12 ounce serving.

The present invention refers to a composition for use in the prevention and/or treatment of orogastrointestinal mucositis induced by oncologic treatments. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of said orogastrointestinal mucositis. Furthermore, it refers to a method of preventing and/or treating of said orogastrointestinal mucositis in which said composition is administered to a subject in need thereof.

The present invention refers to a composition for use in the prevention and/or treatment of orogastrointestinal mucositis induced by oncologic treatments. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of said orogastrointestinal mucositis. Furthermore, it refers to a method of preventing and/or treating of said orogastrointestinal mucositis in which said composition is administered to a subject in need thereof.